Although the mitogenic activators (MEK inhibitor) and CDKs (CDK4/6 inhibitors) play important roles in cell division and regulate transcription, both of them produced the side effect of systemic toxicity or acquired resistance [123] and reduction of neutropenia [124], respectively. Here, MAP2K7 is linked to neutropenia.